Analyst Price Target is $35.00
▲ +588.98% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Moleculin Biotech in the last 3 months. The average price target is $35.00, with a high forecast of $45.00 and a low forecast of $20.00. The average price target represents a 588.98% upside from the last price of $5.08.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Moleculin Biotech. This Buy consensus rating has held steady for over two years.
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Read More